This is an open label phase II study to determine the safety and preliminary efficacy of photoimmunotherapy (PIT) for patients with locally advanced and borderline resectable pancreatic cancer.
Pathologically confirmed pancreatic adenocarcinoma.
Clinically staged locally advanced or borderline resectable pancreatic adenocarcinoma.
Completed neoadjuvant chemotherapy
Neoadjuvant radiation is allowed
Patients with distant metastases.
Patients with medical co-morbidities that make them not candidates for surgical exploration
Planned concomitant, non-protocol directed anti-cancer therapy for at least 8 weeks after ASP-1929
Patients with unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to Grade ≤ 1 or baseline. Note: Subjects may be enrolled with chronic, stable Grade 2.
Brown University
Lead sponsor
Rakuten Medical, Inc.
Collaborator
Rhode Island Hospital
Collaborator
The Miriam Hospital
Collaborator